

## SPECIAL FEATURES

## Highlights of This Issue 6105

## CCR Translations

- 6107** Class Matters: Sensitivity of *BRAF*-Mutant Melanoma to MAPK Inhibition  
Douglas B. Johnson and Kimberly B. Dahlman  
*See related article, p. 6483*
- 6110** Endoglin Targeting in Colorectal Tumor Microenvironment  
Lisa M. Becker and Valerie S. LeBleu  
*See related article, p. 6331*
- 6112** Targeting Resistance to Targeted Therapies: Combating a Resilient Foe  
Siddhartha Devarakonda and Ramaswamy Govindan  
*See related article, p. 6195*

## Reviews

- 6115** Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes  
Alejo Rodriguez-Vida, Jose Luis Perez-Gracia, and Joaquim Bellmunt
- 6125** Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer  
Maartje C.A. Wouters and Brad H. Nelson

## Perspectives



- 6136** Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?  
Sharon R. Pine

## CLINICAL TRIALS: TARGETED THERAPY


- 6142** Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma  
Steven G. DuBois, Yael P. Mosse, Elizabeth Fox, Rachel A. Kudgus, Joel M. Reid, Renee McGovern, Susan Groshen, Rochelle Bagatell, John M. Maris, Clare J. Twist, Kelly Goldsmith, M. Meaghan Granger, Brian Weiss, Julie R. Park, Margaret E. Macy, Susan L. Cohn, Greg Yanik, Lars M. Wagner, Randall Hawkins, Jesse Courtier, Hollie Lai, Fariba Goodarziyan, Hiroyuki Shimada, Najee Boucher, Scarlett Czamecki, Chunqiao Luo, Denice Tsao-Wei, Katherine K. Matthay, and Araz Marachelian
- 6150** Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma  
 Kevin R. Kelly, Jonathan W. Friedberg, Steven I. Park, Kevin McDonagh, John Hayslip, Daniel Persky, Jia Ruan, Soham Puvvada, Peter Rosen, Swaminathan Padmanabhan Iyer, Alexandra Stefanovic, Steven H. Bernstein, Steven Weitman, Anand Karnad, Gregory Monohan, Ari VanderWalde, Raul Mena, Monika Schmelz, Catherine Spier, Susan Groshen, Karthik Venkatakrishnan, Xiaofei Zhou, Emily Sheldon-Waniga, E. Jane Leonard, and Daruka Mahadevan
- 6160** A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan  
Valerie Lee, Judy Wang, Marianna Zahurak, Elske Gootjes, Henk M. Verheul, Rose Parkinson, Zachary Kerner, Anup Sharma, Gary Rosner, Ana De Jesus-Acosta, Daniel Laheru, Dung T. Le, Aram Oganesian, Ellen Lilly, Thomas Brown, Peter Jones, Stephen Baylin, Nita Ahuja, and Nilofer Azad
- 6168** A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium  
 Stephanie Lheureux, Anna Tinker, Blaise Clarke, Prafull Ghatage, Stephen Welch, Johanne I. Weberpals, Neesha C. Dhani, Marcus O. Butler, Katia Tonkin, Qian Tan, David S.P. Tan, Kelly Brooks, Janelle Ramsahai, Lisa Wang, Nhu-An Pham, Patricia A. Shaw, Ming S. Tsao, Swati Garg, Tracey Stockley, and Amit M. Oza



# Table of Contents

## CLINICAL TRIALS: IMMUNOTHERAPY

- 6175** **Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia**  
 Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Jason Hamilton, Rakesh Awasthi, Andrew M. Stein, Denise Sickert, Abhijit Chakraborty, Bruce L. Levine, Carl H. June, Lori Tomassian, Sweta S. Shah, Mimi Leung, Tetiana Taran, Patricia A. Wood, and Shannon L. Maude
- 6185** **A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia**  
 Gunilla Enblad, Hannah Karlsson, Gustav Gammegård, Jessica Wenche, Tanja Lövgren, Rose Marie Amini, Kristina I. Wikstrom, Magnus Essand, Barbara Savoldo, Helene Hallböök, Martin Höglund, Gianpietro Dotti, Malcolm K. Brenner, Hans Hagberg, and Angelica Loskog

## PRECISION MEDICINE AND IMAGING

- 6195** **Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC**  
Xiuning Le, Sonam Puri, Marcelo V. Negrao, Monique B. Nilsson, Jacquelyne Robichaux, Theresa Boyle, J. Kevin Hicks, Katherine L. Lovinger, Emily Roarty, Waree Rinsurongkawong, Ming Tang, Huiying Sun, Yasir Elamin, Lara C. Lacerda, Jeff Lewis, Jack A. Roth, Stephen G. Swisher, J. Jack Lee, William N. William Jr, Bonnie S. Glisson, Jianjun Zhang, Vassiliki A. Papadimitrakopoulou, Jhanelle E. Gray, and John V. Heymach  
*See related commentary, p. 6112*
- 6204** **Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX**  
Amikar Sehdev, Olumide Gbolahan, Brad A. Hancock, Melissa Stanley, Safi Shahda, Jun Wan, Howard H. Wu, Milan Radovich, and Bert H. O'Neil
- 6212** **Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab**  
 Rajiv Raja, Michael Kuziora, Philip Z. Brohawn, Brandon W. Higgs, Ashok Gupta, Phillip A. Dennis, and Koustubh Ranade
- 6223** **Tracking Cell Transplants in Femoral Osteonecrosis with Magnetic Resonance Imaging: A Proof-of-Concept Study in Patients**  
Ashok J. Theruvath, Hossein Nejadnik, Anne M. Muehe, Felix Gassert, Norman J. Lacayo, Stuart B. Goodman, and Heike E. Daldrup-Link

- 6230** **Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: The St Jude Lifetime Cohort Study (SJLIFE)**  
Zhaoming Wang, Qi Liu, Carmen L. Wilson, John Easton, Heather Mulder, Ti-Cheng Chang, Michael C. Rusch, Michael N. Edmonson, Stephen V. Rice, Matthew J. Ehrhardt, Rebecca M. Howell, Chimene A. Kesserwan, Gang Wu, Kim E. Nichols, James R. Downing, Melissa M. Hudson, Jinghui Zhang, Yutaka Yasui, and Leslie L. Robison
- 6236** **Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma**  
David M. Woods, Rupal Ramakrishnan, Addressa S. Laino, Anders Berglund, Kelly Walton, Brian C. Betts, and Jeffrey S. Weber
- 6248** **Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma**  
 Shumei Kato, Ryosuke Okamura, Joel M. Baumgartner, Hitendra Patel, Lawrence Leichman, Kaitlyn Kelly, Jason K. Sicklick, Paul T. Fanta, Scott M. Lippman, and Razelle Kurzrock
- 6257** **Impact of Biomarker-based Design Strategies on the Risk of False-Positive Findings in Targeted Therapy Evaluation**  
Tat-Thang Vo, Alexandre Vivot, and Raphaël Porcher
- 6265** **Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer**  
 Csilla Sipeky, Ping Gao, Qin Zhang, Liang Wang, Otto Ettala, Kirsi M. Talala, Teuvo L.J. Tammela, Anssi Auvinen, Fredrik Wiklund, Gong-Hong Wei, and Johanna Schleutker
- 6277** **Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects**  
Titia G. Meijer, Nicole S. Verkaik, Anieta M. Sieuwerts, Job van Riet, Kishan A.T. Naipal, Carolien H.M. van Deurzen, Michael A. den Bakker, Hein F.B.M. Sleddens, Hendrikus-Jan Dubbink, T. Dorine den Toom, Winand N.M. Dinjens, Esther Lips, Petra M. Nederlof, Marcel Smid, Harmen J.G. van de Werken, Roland Kanaar, John W.M. Martens, Agnes Jager, and Dik C. van Gent

# Table of Contents

- 6288** A Codiclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models

Pascal O. Zinn, Sanjay K. Singh, Aikaterini Kotrotsou, Islam Hassan, Ginu Thomas, Markus M. Luedi, Ahmed Elakkad, Nabil Elshafeey, Tagwa Idris, Jennifer Mosley, Joy Gumin, Gregory N. Fuller, John F. de Groot, Veera Baladandayuthapani, Erik P. Sulman, Ashok J. Kumar, Raymond Sawaya, Frederick F. Lang, David Piwnica-Worms, and Rivka R. Colen

- 6300** PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact

Bernhard Grubmüller, Pascal Baltzer, Sabrina Hartenbach, David D'Andrea, Thomas H. Helbich, Alexander R. Haug, Gregor M. Goldner, Wolfgang Wadsak, Sarah Pfaff, Markus Mitterhauser, Theresa Balber, Neydher Berroteran-Infante, Marko Grahovac, John Babich, Christian Seitz, Gero Kramer, Martin Susani, Peter Mazal, Lukas Kenner, Shahrokh F. Shariat, Marcus Hacker, and Markus Hartenbach

## TRANSLATIONAL CANCER MECHANISMS AND THERAPY

- 6308** Loss of Function of Canonical Notch Signaling Drives Head and Neck Carcinogenesis

Patrick E. Nyman, Darya Buehler, and Paul F. Lambert

- 6319** PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder through Sponging miR-30c to Induce Epithelial-Mesenchymal Transition

Xin Chen, Ri-Xin Chen, Wen-Su Wei, Yong-Hong Li, Zi-Hao Feng, Lei Tan, Jie-Wei Chen, Gang-Jun Yuan, Si-Liang Chen, Sheng-Jie Guo, Kang-Hua Xiao, Zhuo-Wei Liu, Jun-Hang Luo, Fang-Jian Zhou, and Dan Xie

- 6331** Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis

Madelon Paauwe, Mark J.A. Schoonderwoerd, Roxan F.C.P. Helderma, Tom J. Harryvan, Arwin Groenewoud, Gabi W. van Pelt, Rosalie Bor, Danielle M. Hemmer, Henri H. Versteeg, B. Ewa Snaar-Jagalska, Charles P. Theuer, James C.H. Hardwick, Cornelis F.M. Sier, Peter ten Dijke, and Lukas J.A.C. Hawinkels  
*See related commentary, p. 6110*

- 6345** Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, Hideo Yagita, Martina Friess, Beata Bode, Isabelle Opitz, Bart Vrugt, Walter Weder, Paul Stolzmann, Emanuela Felley-Bosco, Rolf A. Stahel, Verena Tischler, Christian Britschgi, Davide Soldini, Maries van den Broek, and Alessandra Curioni-Fontecedro

- 6355** Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling

Thai H. Tran, Fransiscus E. Utama, Takahiro Sato, Amy R. Peck, John F. Langenheimer, Sameer S. Udhan, Yunguang Sun, Chengbao Liu, Melanie A. Gironde, Albert J. Kovatich, Jeffrey A. Hooke, Craig D. Shriver, Hai Hu, Juan P. Palazzo, Marluce Bibbo, Paul W. Auer, Michael J. Flister, Terry Hyslop, Edith P. Mitchell, Inna Chervoneva, and Hallgeir Rui

- 6367** Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer

Olga Méndez, Vicente Peg, Cándida Salvans, Mireia Pujals, Yolanda Fernández, Ibane Abasolo, José Pérez, Ana Matres, Marta Valeri, Josep Gregori, Laura Villarreal, Simó Schwartz Jr, Santiago Ramon y Cajal, Josep Tabernero, Javier Cortés, Joaquín Arribas, and Josep Villanueva

- 6383** Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy

Ashley Orillion, Nur P. Damayanti, Li Shen, Remi Adelaiye-Ogala, Hayley Affronti, May Elbanna, Sreenivasulu Chintala, Michael Ciesielski, Luigi Fontana, Chinghai Kao, Bennett D. Elzey, Timothy L. Ratliff, David E. Nelson, Dominic Smiraglia, Scott I. Abrams, and Roberto Pili

- 6396** Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

Cheryl A. London, Jaime Acquaviva, Donald L. Smith, Manuel Sequeira, Luisa Shin Ogawa, Heather L. Gardner, Louis Feo Bernabe, Misty D. Bear, Sandra A. Bechtel, and David A. Proia




# Table of Contents

- 6408** Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191  
Haiwen Ni, Fazal Shirazi, Veerabhadran Baladandayuthapani, Heather Lin, Isere Kuitse, Hua Wang, Richard J. Jones, Zuzana Berkova, Yasumichi Hitoshi, Stephen M. Ansell, Steven P. Treon, Sheeba K. Thomas, Hans C. Lee, Zhiqiang Wang, R. Eric Davis, and Robert Z. Orlowski
- 6421** *BMI1* Drives Metastasis of Prostate Cancer in Caucasian and African-American Men and Is A Potential Therapeutic Target: Hypothesis Tested in Race-specific Models  
Arsheed A. Ganaie, Firdous H. Beigh, Matteo Astone, Marina G. Ferrari, Raihana Maqbool, Syed Umbreen, Aijaz S. Parry, Hifzur R. Siddique, Tabish Hussain, Paari Murugan, Colm Morrissey, Shahriar Koochekpour, Yibin Deng, Badrinath R. Konety, Luke H. Hoepfner, and Mohammad Saleem
- 6433** Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer  
Sandeep Shelar, Eun-Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler Poston, Jubilee Tan, Vishwas Parekh, Daniel Benson, David K. Crossman, Phillip J. Buckhaults, Dinesh Rakheja, Richard Kirkman, Yusuke Sato, Seishi Ogawa, Shilpa Dutta, Sadanandan E. Velu, Ethan Emberley, Alison Pan, Jason Chen, Tony Huang, Devin Absher, Anja Becker, Conrad Kunick, and Sunil Sudarshan
- 6447** IFN $\gamma$ -induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody  
Ji Li, Ryan Ybarra, Judy Mak, Aurelie Herault, Patricia De Almeida, Alfonso Arrazate, James Ziai, Klara Totpal, Melissa R. Junttila, Kevin B. Walsh, and Teemu T. Junttila
- 6459** Kub5-Hera<sup>RPRD1B</sup> Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers  
Edward A. Motea, Farjana J. Fattah, Ling Xiao, Luc Girard, Amy Rommel, Julio C. Morales, Praveen Patidar, Yunyun Zhou, Andrew Porter, Yang Xie, John D. Minna, and David A. Boothman
- 6471** Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma  
Monika A. Davare, Jacob J. Henderson, Anupriya Agarwal, Jacob P. Wagner, Sudarshan R. Iyer, Nameeta Shah, Randy Woltjer, Romel Somwar, Stephen W. Gilheeny, Ana DeCarvalo, Tom Mikkelsen, Erwin G. Van Meir, Marc Ladanyi, and Brian J. Druker
- 6483** Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas  
Matthew Dankner, Mathieu Lajoie, Dan Moldoveanu, Tan-Trieu Nguyen, Paul Savage, Shivshankari Rajkumar, Xiu Huang, Maria Lvova, Alexei Protopopov, Dana Vuzman, David Hogg, Morag Park, Marie-Christine Guiot, Kevin Petrecca, Catalin Mihalciou, Ian R. Watson, Peter M. Siegel, and April A.N. Rose  
*See related commentary, p. 6107*
- 6495**  *RAB37* Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma  
Yingqin Li, Xiaojing Yang, Xiaojing Du, Yuan Lei, Qingmei He, Xiaohong Hong, Xinran Tang, Xin Wen, Panpan Zhang, Ying Sun, Jian Zhang, Yaqin Wang, Jun Ma, and Na Liu
- 6509**  Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer  
Rayna Rosati, Lisa Polin, Charles Ducker, Jing Li, Xun Bao, Dakshnamurthy Selvakumar, Seongho Kim, Besa Xhabija, Martha Larsen, Thomas McFall, Yanfang Huang, Benjamin L. Kidder, Andrew Fribley, Janice Saxton, Hiroki Kakuta, Peter Shaw, and Manohar Ratnam
- 6523** MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type EGFR Family Members  
Dan Yan, Rebecca E. Parker, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp III, Deborah DeRyckere, and Douglas K. Graham
- 6536** Methylomic Analysis of Ovarian Cancers Identifies Tumor-Specific Alterations Readily Detectable in Early Precursor Lesions  
Thomas R. Pisanic II, Leslie M. Cope, Shiou-Fu Lin, Ting-Tai Yen, Pornpat Athamanolap, Ryoichi Asaka, Kentaro Nakayama, Amanda N. Fader, Tza-Huei Wang, Ie-Ming Shih, and Tian-Li Wang
- 6548** EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas  
Susan E. Jorge, Antonio R. Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R. Oxnard, Deepa Rangachari, Mark S. Huberman, Lecia V. Sequist, Susumu S. Kobayashi, and Daniel B. Costa
- 6556** *KMT2C* Mutations in Diffuse-Type Gastric Adenocarcinoma Promote Epithelial-to-Mesenchymal Transition  
Soo-Jeong Cho, Changhwan Yoon, Jun Ho Lee, Kevin K. Chang, Jian-xian Lin, Young-Ho Kim, Myeong-Cherl Kook, Bülent Arman Aksoy, Do Joong Park, Hassan Ashktorab, Duane T. Smoot, Nikolaus Schultz, and Sam S. Yoon

# Table of Contents


- 6570** SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads  
Krista Kinneer, John Meekin, Arnaud C. Tiberghien, Yu-Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos, Sriram Sridhar, Stephen J. Gregson, Michael J. Wick, Luke Masterson, Kenneth C. Anderson, Ronald Herbst, Philip W. Howard, and David A. Tice

- 6583** Lack of DNA Damage Response at Low Radiation Doses in Adult Stem Cells Contributes to Organ Dysfunction  
 Peter W. Nagle, Nynke A. Hosper, Lara Barazzuol, Anne L. Jellema, Mirjam Baanstra, Marc-Jan van Goethem, Sytze Brandenburg, Ulrich Giesen, Johannes A. Langendijk, Peter van Luijk, and Rob P. Coppes

- 6594** Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition  
Xian Chen, Kwang-Huei Low, Angela Alexander, Yufeng Jiang, Cansu Karakas, Kenneth R. Hess, Jason P.W. Carey, Tuyen N. Bui, Smruthi Vijayaraghavan, Kurt W. Evans, Min Yi, D. Christian Ellis, Kwok-Leung Cheung, Ian O. Ellis, Siqing Fu, Funda Meric-Bernstam, Kelly K. Hunt, and Khandan Keyomarsi


## Letters to the Editor

- 6611** Molecular Profiling of Pancreatic Cancer Patients—Letter  
Ibrahim H. Sahin and Harold Elias
- 6612** Molecular Profiling of Pancreatic Cancer Patients—Response  
Michael J. Pishvaian and Emanuel Petricoin III

 AC icon indicates AuthorChoice  
For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

The cover shows an invasive front of a breast tumor derived from an orthotopic xenograft of the MDA231i cells. The image shows how HMGA1 expression (green) is enriched in the invasive front of the tumor. Cytokeratin (red) is used to stain human epithelial cells, and Hoechst to counterstain the nuclei. For details, see the article by Méndez and colleagues on page 6367 of this issue.



# Clinical Cancer Research

**24 (24)**

*Clin Cancer Res* 2018;24:6105-6612.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/24/24>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/24/24>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.